Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.

BACKGROUND: The absence of specific antivirals to treat COVID-19 leads to the repositioning of candidates’ drugs. Nitazoxanide (NTZ) has a broad antiviral effect. METHODS: This was a randomized, double-blind pilot clinical trial comparing NTZ 600 mg BID versus Placebo for seven days among 50 individ...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:EClinicalMedicine
Auteurs principaux: Blum, Vinicius Fontanesi, Cimerman, Sérgio, Hunter, James R, Tierno, Paulo, Lacerda, Acioly, Soeiro, Alexandre, Cardoso, Florentino, Bellei, Nancy Cristina, Maricato, Juliana, Mantovani, Nathalia, Vassao, Marcella, Dias, Danilo, Galinskas, Juliana, Janini, Luis Mário Ramos, Santos-Oliveira, Joanna Reis, Da-Cruz, Alda Maria, Diaz, Ricardo Sobhie
Format: Artigo
Langue:Inglês
Publié: Elsevier 2021
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC8235996/
https://ncbi.nlm.nih.gov/pubmed/34222847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eclinm.2021.100981
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires